Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Asthma-I: Introduction01:29

Asthma-I: Introduction

Asthma is a chronic respiratory ailment that requires careful management due to its varying symptoms and influencing factors. It is characterized by airway inflammation, bronchial hyperresponsiveness, and reversible airflow obstruction, leading to symptoms like wheezing, shortness of breath, chest tightness, and coughing. The symptom frequency and intensity may vary considerably over time. It is also linked to immune system responses to allergens and irritants, highlighting the complex...
Asthma-II: Pathophysiology and Classification01:26

Asthma-II: Pathophysiology and Classification

Asthma is a prevalent chronic respiratory condition marked by inflammation and hyperresponsiveness of the airways. Its pathophysiology involves complex interactions among inflammatory pathways, immune responses, and neural mechanisms.
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
Asthma I: Introduction01:28

Asthma I: Introduction

Asthma is a chronic inflammatory disorder of the airways characterized by variable airflow obstruction and heightened bronchial responsiveness to a wide range of triggers. The underlying inflammation leads to airway swelling, mucus hypersecretion, and smooth muscle constriction, all of which narrow the airway lumen and impede airflow. Clinically, asthma presents with recurrent episodes of wheezing, shortness of breath, chest tightness, and coughing, symptoms that typically vary in intensity and...
Asthma III: Clinical Manifestations01:13

Asthma III: Clinical Manifestations

Asthma presents with a characteristic pattern of episodic respiratory symptoms that reflect underlying airway inflammation, bronchoconstriction, and mucus hypersecretion. Although severity varies among individuals, certain clinical manifestations are considered hallmarks of the disorder and often guide diagnosis and assessment.Respiratory SymptomsA persistent cough is one of the most common early features of asthma. It is frequently dry and tends to worsen at night or in the early morning,...
Asthma: Pathogenesis and Management01:20

Asthma: Pathogenesis and Management

Asthma is a chronic pulmonary condition involving inflammation of the airways, hyper-reactivity, and reversible obstruction of the airways. This condition can significantly impact a person's quality of life, making breathing difficult and leading to distressing symptoms.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs01:25

Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs

Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Rapid generation of a sdhb loss-of-function zebrafish model for secreting pheochromocytomas and paragangliomas.

NPJ genomic medicine·2025
Same author

Rhinitis associated with asthma is distinct from rhinitis alone: The ARIA-MeDALL hypothesis.

Allergy·2023
Same author

Identification by cluster analysis of patients with asthma and nasal symptoms using the MASK-air® mHealth app.

Pulmonology·2022
Same author

Sputum Inflammatory Patterns Are Associated With Distinct Clinical Characteristics in Patients with Occupational Asthma Independently of the Causal Agent.

Journal of investigational allergology & clinical immunology·2022
Same author

Respiratory Disease Occupational Biomonitoring Collaborative Project (ROBoCoP): A longitudinal pilot study and implementation research in the Parisian transport company.

Journal of occupational medicine and toxicology (London, England)·2021
Same author

Biorefinery potential of sustainable municipal wastewater treatment using fast-growing willow.

The Science of the total environment·2021

Related Experiment Video

Updated: May 22, 2026

Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma
14:39

Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma

Published on: November 4, 2010

Occupational asthma: new low-molecular-weight causal agents, 2000-2010.

J A Pralong1, A Cartier, O Vandenplas

  • 1Department of Chest Medicine, Sacré-Cœur Hospital, University of Montreal, QC, Canada H4J 1C5.

Journal of Allergy
|May 2, 2012
PubMed
Summary

New low-molecular-weight (LMW) agents causing occupational asthma (OA) are continually identified. This review details 41 new LMW agents identified between 2000-2010, emphasizing the need for ongoing vigilance in occupational health surveillance.

More Related Videos

Generation of a Chronic Obstructive Pulmonary Disease Model in Mice by Repeated Ozone Exposure
08:17

Generation of a Chronic Obstructive Pulmonary Disease Model in Mice by Repeated Ozone Exposure

Published on: August 25, 2017

Measuring Carbon Content in Airway Macrophages Exposed to Carbon-Containing Particulate Matters
05:18

Measuring Carbon Content in Airway Macrophages Exposed to Carbon-Containing Particulate Matters

Published on: July 12, 2024

Related Experiment Videos

Last Updated: May 22, 2026

Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma
14:39

Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma

Published on: November 4, 2010

Generation of a Chronic Obstructive Pulmonary Disease Model in Mice by Repeated Ozone Exposure
08:17

Generation of a Chronic Obstructive Pulmonary Disease Model in Mice by Repeated Ozone Exposure

Published on: August 25, 2017

Measuring Carbon Content in Airway Macrophages Exposed to Carbon-Containing Particulate Matters
05:18

Measuring Carbon Content in Airway Macrophages Exposed to Carbon-Containing Particulate Matters

Published on: July 12, 2024

Area of Science:

  • Occupational Health
  • Immunology
  • Toxicology

Background:

  • Over 400 agents are known to cause occupational asthma (OA).
  • The expanding list of low-molecular-weight (LMW) agents implicated in OA necessitates continuous literature review.
  • Identifying novel LMW sensitizers is crucial for occupational health management.

Purpose of the Study:

  • To identify and categorize new low-molecular-weight (LMW) agents causing occupational asthma (OA).
  • To cover the literature published between 2000 and 2010 for novel OA-inducing LMW agents.

Main Methods:

  • A systematic Medline search was conducted.
  • Keywords included "occupational asthma," "new allergens," "new causes," and "low-molecular-weight agents."
  • Identified agents were categorized by type (drugs, wood dust, chemicals, metals, biocides, miscellaneous).

Main Results:

  • 39 publications identified 41 new LMW causal agents for occupational asthma (OA).
  • These agents included 12 drugs, 11 wood dusts, 8 chemicals, 4 metals, 3 biocides, and 3 miscellaneous agents.
  • Diagnosis was confirmed by specific inhalation challenge (SIC) for 35 agents, peak expiratory flow monitoring for 3, and clinical history for 3. Immunological evidence (IgE-mediated) was found for 8 agents (20%).

Conclusions:

  • The study underscores the emergence of new low-molecular-weight (LMW) sensitizers causing occupational asthma (OA).
  • Healthcare professionals must remain vigilant for novel LMW agents that can induce OA.
  • A type I hypersensitivity mechanism was implicated in 20% of the newly identified LMW agents.